A groundbreaking study published by researchers at the Harry Perkins Institute of Medical Research in Australia revealed that melittin, the active compound in honeybee venom, can selectively kill aggressive breast cancer cells, including triple-negative breast cancer (TNBC) and HER2-enriched types.
These types are particularly difficult to treat due to their resistance to conventional therapies.
Key findings include:
Melittin disrupted the cancer cells’ plasma membranes and interfered with signaling pathways essential for tumor growth.
Within 60 minutes, melittin was able to significantly reduce the viability of cancer cells.
Most notably, the venom did not affect normal breast cells, highlighting its therapeutic potential.
The study also suggested combination therapy with chemotherapy, showing enhanced effectiveness.
However, it's important to note that this research is still in the preclinical phase, primarily conducted in lab settings and mice.
Further clinical trials in humans are necessary to confirm its safety and efficacy before being considered a treatment option.
These types are particularly difficult to treat due to their resistance to conventional therapies.
Key findings include:
Melittin disrupted the cancer cells’ plasma membranes and interfered with signaling pathways essential for tumor growth.
Within 60 minutes, melittin was able to significantly reduce the viability of cancer cells.
Most notably, the venom did not affect normal breast cells, highlighting its therapeutic potential.
The study also suggested combination therapy with chemotherapy, showing enhanced effectiveness.
However, it's important to note that this research is still in the preclinical phase, primarily conducted in lab settings and mice.
Further clinical trials in humans are necessary to confirm its safety and efficacy before being considered a treatment option.
A groundbreaking study published by researchers at the Harry Perkins Institute of Medical Research in Australia revealed that melittin, the active compound in honeybee venom, can selectively kill aggressive breast cancer cells, including triple-negative breast cancer (TNBC) and HER2-enriched types.
These types are particularly difficult to treat due to their resistance to conventional therapies.
Key findings include:
Melittin disrupted the cancer cells’ plasma membranes and interfered with signaling pathways essential for tumor growth.
Within 60 minutes, melittin was able to significantly reduce the viability of cancer cells.
Most notably, the venom did not affect normal breast cells, highlighting its therapeutic potential.
The study also suggested combination therapy with chemotherapy, showing enhanced effectiveness.
However, it's important to note that this research is still in the preclinical phase, primarily conducted in lab settings and mice.
Further clinical trials in humans are necessary to confirm its safety and efficacy before being considered a treatment option.
0 Comments
·0 Shares
·15K Views